[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.241.199. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
October 18, 2006

Sirolimus-Eluting Stents vs Brachytherapy for Restenosis

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;296(15):1837-1838. doi:10.1001/jama.296.15.1837-c

To the Editor: Dr Holmes and colleagues1 reported the results of the Sirolimus-Eluting Stent vs Brachytherapy in Patients With Bare Metal In-Stent Restenosis (SISR) trial, in which they demonstrated that sirolimus-eluting stents are superior to brachytherapy in patients with in-stent restenosis. Rather than merely abandoning brachytherapy because of logistical difficulties, it would be helpful if the authors provided additional information.

First Page Preview View Large
First page PDF preview
First page PDF preview
×